Palivizumab (Intramuscular Route)


Free

E-newsletter

Subscribe to Housecall

Our weekly general interest
e-newsletter keeps you up to date on a wide variety of health topics.

Sign up now

Palivizumab (Intramuscular Route)

Drug Information provided by: Micromedex

US Brand Names

  • Synagis

Description

Palivizumab injection is used to prevent serious lung infection in children and babies caused by respiratory syncytial virus (RSV). It belongs to a group of medicines known as immunizing agents. This medicine works by giving your body antibodies to protect it against RSV infection.

RSV infection can cause serious problems that affect the lungs, such as pneumonia and bronchitis, and in severe cases can even cause death. These problems are more likely to occur in infants and children younger than 6 months of age with chronic lung disease and breathing problems. Babies who were born premature or babies who were born with heart disease may also have problems with RSV.

The onset of RSV activity usually occurs in November and continues through April, but it may begin earlier or continue later in certain communities. A good way to help prevent RSV infection is to receive palivizumab before the start of the RSV season.

This medicine is to be given only by or under the direct supervision of your doctor.

This product is available in the following dosage forms:

  • Powder for Solution
  • Solution
Before Using
DR601057 Portions of this document last updated: June 1, 2012

Source: Drug Information provided by: Micromedex

Copyright © 2013 Thomson Healthcare Inc. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.

Advertisement


Text Size: smaller largerlarger